Related Experiment Videos
Somatostatin analogs in the management of gastrointestinal tumors
1Department of Medicine, Erasmus University, Rotterdam, The Netherlands.
Abstract:
Experience with SMS 201-995 (Sandostatin), a somatostatin analog, in the treatment of endocrine active gastrointestinal tumors is reviewed. Best immediate results were obtained in vipomas and insulinomas but a scape phenomenon was frequently observed. A positive and persistent effect was recorded in a case of nesidioblastosis. It was striking that good clinical control could be obtained in some instances despite insufficient suppression of hormone secretion by the tumor. This finding suggests peripheral actions of somatostatin and SMS independently of its primary effect on hormone release.
Insights
Sandostatin (SMS 201-995), a somatostatin analog, effectively treats endocrine gastrointestinal tumors like vipomas and insulinomas. Clinical control was observed even without full hormone suppression, suggesting additional peripheral actions.
Area of Science:
- Endocrinology
- Gastroenterology
- Oncology
Background:
- Review of Sandostatin (SMS 201-995), a somatostatin analog, for treating endocrine-active gastrointestinal tumors.
- Assessment of its efficacy and observed phenomena during treatment.
Observation:
- Immediate positive results noted in vipomas and insulinomas.
- Frequent occurrence of a 'scape phenomenon' (loss of efficacy) was observed.
- A persistent positive effect was documented in a case of nesidioblastosis.
Findings:
- Good clinical control achieved in some cases despite incomplete suppression of tumor hormone secretion.
- This suggests somatostatin and SMS may exert peripheral actions independent of direct hormone release inhibition.
Implications:
- Potential for novel therapeutic strategies targeting somatostatin's peripheral effects.
- Further research into the mechanisms of Sandostatin beyond hormone suppression is warranted.
- Highlights the complex interplay between tumor hormone secretion and clinical outcomes.